Topoisomerase II alpha protein and responsiveness of breast cancer to adjuvant chemotherapy with CEF compared to CMF in the NCIC CTG randomized MA.5 adjuvant trial

Breast Cancer Research and Treatment

Volumn 128, Issue 2, 2011, Pages 401-409

  O'Malley, F P ^a,b   Chia, S ^c,d   Tu, D ^e   Shepherd, L E ^e   Levine, M N ^f   Huntsman, D ^c,d   Bramwell, V H ^g,h   Andrulis, I L ^a,i   Pritchard, K I ^a,j  

^a UNIVERSITY OF TORONTO   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e Queen's Cancer Research Institute   (Canada)

^f MCMASTER UNIVERSITY   (Canada)

^g TOM BAKER CANCER CENTRE   (Canada)

^h UNIVERSITY OF CALGARY   (Canada)

ⁱ MOUNT SINAI HOSPITAL   (Canada)

^j DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

more..

Author keywords

Adjuvant anthracycline chemotherapy; Topoisomerase II alpha protein

Indexed keywords

CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE (ATP HYDROLYSING) A; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; METHOTREXATE;

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GENE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MASTECTOMY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RELAPSE FREE SURVIVAL; SURVIVAL; TOP2A GENE;

ADULT; ANTIGENS, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; EPIRUBICIN; FEMALE; FLUOROURACIL; GENE AMPLIFICATION; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION, FLUORESCENCE; METHOTREXATE; MIDDLE AGED; RECEPTOR, ERBB-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 79959705252     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1511-5     Document Type: Article

References (33)

1. KI Pritchard LE Shepherd FP O'Malley, et al. 2006 HER2 and responsiveness of breast cancer to adjuvant chemotherapy New Eng J Med 354 2103 2111 16707747 10.1056/NEJMoa054504 1:CAS:528:DC%2BD28XkslCku7s%3D (Pubitemid 43736610)
2. A Gennari M Sormani M Puntoni P Bruzzi 2006 A pooled analysis on the interaction between Her-2 expression and responsiveness of breast cancer to adjvuant chemotherapy [abstract] Breast Can Res Treat 100 S19
3. B Dhesy-Thind KI Pritchard H Messersmith F O'Malley L Elavathil M Trudeau 2007 Her-2/neu in systemic therapy for women with breast cancer: a systemic review Br Can Res Treat 109 209 229 10.1007/s10549-007-9656-y Online
4. M De Laurentiis G Arpino E Massarelli, et al. 2005 A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer Clin Cancer Res 11 4741 4748 16000569 10.1158/1078-0432.CCR-04-2569 (Pubitemid 41557193)
5. F O'Malley S Chia D Tu, et al. 2009 Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy J Nat Cancer Inst 101 644 650 19401546 10.1093/jnci/djp067
6. AS Knoop H Knudsen E Balslev, et al. 2005 Retrospective analysis of Topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish breast cancer cooperative group J Clin Oncol 23 7483 7490 16234514 10.1200/JCO.2005.11. 007 1:CAS:528:DC%2BD2MXht1WrsrzK (Pubitemid 46291811)
7. M Tanner J Isola T Wiklund, et al. 2006 Topoisomerase II alpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian breast cancer trial 9401 J Clin Oncol 24 2428 2436 16682728 10.1200/JCO.2005.02.9264 1:CAS:528:DC%2BD28XmtVOmsLc%3D (Pubitemid 46630618)
8. RE Mueller RK Parkes I Andrulis FP O'Malley 2004 Amplification of the TOP2A gene does not predict high levels of Topoisomerase II alpha protein in human breast tumor samples Genes Chromosom Cancer 39 288 297 14978790 10.1002/gcc.20008 1:CAS:528:DC%2BD2cXivFKjsbw%3D (Pubitemid 38326310)
9. YY Mo WT Beck 1997 Heterogeneous expression of DNA topoisomerase II alpha isoforms in tumor cell lines Oncol Res 9 193 204 9268990 1:CAS:528: DyaK1cXhtlOnsbo%3D (Pubitemid 127827757)
10. AK Tandon GM Clark GC Chamness, et al. 1989 Her-2/neu oncogene protein and prognosis in breast cancer J Clin Oncol 7 1120 1128 2569032 1:STN:280:DyaL1MzivVCruw%3D%3D (Pubitemid 19196537)
11. A Di Leo D Larsimont D Gabcberg, et al. 2001 HER-2 and topoisomerase II alpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide Annals of Oncol 12 1081 1089 10.1023/A:1011669223035 (Pubitemid 32834488)
12. V Durbecq M Paesmans F Cardoso, et al. 2004 Topoisomerase-II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel Mol Cancer Ther 3 1207 1214 15486187 1:CAS:528:DC%2BD2cXosVSrs74%3D (Pubitemid 39440165)
13. MN Levine VH Bramwell KI Pritchard, et al. 1998 A randomized trial of cyclophosphamide, epirubicin, fluorouracil chemotherapy compared with cyclophosphamide, methrotrexate, fluorouracil in premenopausal women with node positive breast cancer J Clin Oncol 16 2651 2658 9704715 1:CAS:528: DyaK1cXlsFCguro%3D (Pubitemid 28363028)
14. MN Levine KI Pritchard VH Bramwell L Shepherd D Tu N Paul 2005 A randomized trial comparing CEF to CMF in premenopausal women with node positive breast cancer: update of NCIC CTG MA.5 J Clin Oncol 23 5166 5170 16051958 10.1200/JCO.2005.09.423 1:CAS:528:DC%2BD2MXpsFWmtb8%3D (Pubitemid 46224025)
15. AA Lazar BF Cole M Bonetti RD Gelber 2010 Evaluation of treatment-effect heterogeneity using biomarkers measured on a continuous scale: subpopulation treatment effect pattern plot J Clin Oncol 28 4539 4544 20837942 10.1200/JCO.2009.27.9182
16. JC Brase M Schmidt T Fischbach, et al. 2010 Erb B2 and TOP2A in breast cancer: a comprehensive analysis of gene amplification, RNA levels and protein expression and their influence on prognosis and prediction Clin Cancer Res 16 2391 2401 20371687 10.1158/1078-0432.CCR-09-2471 1:CAS:528:DC%2BC3cXkslSls70%3D
17. M Campiglio G Somenzi C Olgiati, et al. 2003 Role of proliferation in HER2 status predicted response to doxorubicin Int J Cancer 105 568 573 12712452 10.1002/ijc.11113 1:CAS:528:DC%2BD3sXktlOqsbY%3D (Pubitemid 36578565)
18. D Slamon W Eiermann N Robert, et al. 2007 BCIRG 006: 2nd Interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC/ET) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC/ETH) with docetaxel carboplatin and trastuzumab (TCH) in Her-2/neu positive early breast cancer patients [abstract] Breast Cancer Res Treat 106 S147
19. C Schindlbeck D Mayr C Olivier, et al. 2010 Topoisomerase II alpha expression rather than gene amplification predicts responsiveness of adjuvant anthracycline-based chemotherapy in women with primary breast cancer J Cancer Res Clin Oncol 10.1007/s00432-990-0748-4 20052594
20. C Schindlebeck W Janni N Shabani, et al. 2005 Isolated tumor cells in the bone marrow (ITC-BM) of breast cancer patients before and after anthracline based therapy: influenced by the HER2 and topoisomerase II alpha status of the primary tumor? J Cancer Res Clin Oncol 131 539 546 10.1007/s00432-005-0683-y (Pubitemid 41215309)
21. P Fritz CM Cabrera J Dippon, et al. 2005 c-erbB2 and topoisomerase II alpha protein expression independently predict poor survival in primary human breast cancer: a retrospective study Br Cancer Res 7 R374 R384 10.1185/.bcr1012 10.1186/bcr1012 1:CAS:528:DC%2BD2MXkt1equrg%3D
22. AM Minisini C Di Lorefto M Mansutti, et al. 2005 Topoisomerase II alpha and APE/ref-1 are associated with pathologic response to primary anthracycline-based chemotherapy for breast cancer Cancer Lett 224 133 139 15911109 10.1016/j.canlet.2004.11.007 1:CAS:528:DC%2BD2MXks1aktr0%3D (Pubitemid 40720374)
23. G Arpino DR Ciocca H Weiss, et al. 2005 Predictive value of apoptosis, proliferation, HER-2, and topoisomerase II alpha for anthracycline chemotherapy in locally advanced breast cancer Br Cancer Res Treat 92 69 75 10.1007/s10549-005-1721-9 1:CAS:528:DC%2BD2MXls1Sms74%3D (Pubitemid 40875080)
24. L Zhu L Ya-fen WG Chen, et al. 2008 HER2 and topoisomerase II alpha: possible predictors of response to neoadjuvant chemotherapy for breast cancer patients Chinese Med J 121 1965 1968
25. M Martin-Richard M Munoz J Albanell L Colomo, et al. 2004 Serial topoisomerase II expression in primary breast cancer and response to neoadjuvant anthracycline-based chemotherapy Oncology 66 388 394 15331926 10.1159/000079487 1:CAS:528:DC%2BD2cXntFSgt74%3D (Pubitemid 39194361)
26. G MacGrogan P Rudolph I de Mascarel, et al. 2003 DNA topoisomerase II alpha expression and the response to primary chemotherapy in breast cancer Br J Cancer 89 666 671 12915875 10.1038/sj.bjc.6601185 1:CAS:528:DC%2BD3sXmtFKqtrg%3D (Pubitemid 37076170)
27. V Dubecq C Desmedt M Paesmans F Cardoso, et al. 2004 Correlation between topoisomerase II alpha gene amplification and protein expression in HER2 amplified breast cancer Int J Oncol 25 1473 1479
28. F Cardoso V Durbecq D Larsimont M Paesmans, et al. 2004 Correlation between complete response to anthracycline-based chemotherapy and topoisomerase II alpha gene amplification and protein overexpression in locally advanced/metastatic breast cancer Int J Oncol 24 201 209 14654958 1:CAS:528:DC%2BD2cXktlWhtw%3D%3D
29. MF Press G Sauter M Buyse, et al. 2010 Alteration of topoisomerase II-Alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy JCO 10.1200/JCO.2009.27.5644 published online
30. JMS Bartlett A Munro DA Cameron J Thomas R Prescott C Twelves 2008 Type I receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial J Clin Oncol 26 5027 5035 18768436 10.1200/JCO.2007.14.6597 1:CAS:528: DC%2BD1cXhsVGhsrrE
31. A Di Leo D Gancberg D Larsimont M Tanner TA Jarvinen G Rouas 2002 HER-2 amplification and topoisomerase II alpha gene aberrations as predictive markers in node positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil Clin Cancer Res 8 1107 1116 12006526 (Pubitemid 34517647)
32. CJ Poole H Earl L Hiller, et al. 2006 Epirubicin and cyclophosphamide, methotrexate, and fluourouracil as adjuvant therapy for early breast cancer New Engl J Med 355 1851 1862 17079759 10.1056/NEJMoa052084 1:CAS:528: DC%2BD28XhtFKjsLjP (Pubitemid 44664643)
33. A Di Leo C Desmedt JMS Bartlett, et al. 2010 Final results of a meta-analysis testing HER2 and topoisomerase II genes as predictors of incremental benefit from anthracyclines in breast cancer J Clin Oncol 28 72S Abstract 519